Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ligand Pharmaceuticals Incorporated LGND
$75.70
-$1.96 (-2.59%)
На 18:00, 12 мая 2023
+18.89%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
1333084194.00000000
-
week52high
85.70
-
week52low
45.27
-
Revenue
196245000
-
P/E TTM
-44
-
Beta
0.98339100
-
EPS
-0.30000000
-
Last Dividend
9.35745500
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Barclays | Overweight | Overweight | 05 июл 2022 г. |
| Stephens & Co. | Overweight | Overweight | 16 мая 2022 г. |
| Benchmark | Buy | Buy | 22 февр 2022 г. |
| Barclays | Overweight | Overweight | 18 февр 2022 г. |
| Barclays | Overweight | Overweight | 22 сент 2021 г. |
| Roth Capital | Buy | Buy | 02 сент 2022 г. |
| Barclays | Overweight | Overweight | 25 окт 2022 г. |
| Barclays | Overweight | Overweight | 21 ноя 2022 г. |
| Roth Capital | Buy | Buy | 23 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| HIGGINS JOHN L | D | 417695 | 5289 | 28 дек 2022 г. |
| Korenberg Matthew E | D | 92569 | 3859 | 28 дек 2022 г. |
| HIGGINS JOHN L | A | 92932 | 92932 | 22 дек 2022 г. |
| Korenberg Matthew E | A | 25967 | 25967 | 22 дек 2022 г. |
| Gray Nancy Ryan | A | 3050 | 3050 | 22 дек 2022 г. |
| KOZARICH JOHN W | A | 6623 | 6623 | 22 дек 2022 г. |
| LAMATTINA JOHN L | A | 4484 | 4484 | 22 дек 2022 г. |
| Sabba Stephen L | A | 6623 | 6623 | 22 дек 2022 г. |
| Espinoza Octavio | A | 6620 | 6620 | 22 дек 2022 г. |
| Davis Todd C | A | 2081 | 2081 | 22 дек 2022 г. |
Новостная лента
Ligand (LGND) Up 3% on Raised '23 View, Beats on Q1 Earnings
Zacks Investment Research
08 мая 2023 г. в 13:43
Ligand Pharmaceuticals (LGND) announces better-than-expected results in first-quarter 2023. Management raises 2023 financial outlook.
Wall Street Analysts Believe Ligand (LGND) Could Rally 38.66%: Here's is How to Trade
Zacks Investment Research
08 мая 2023 г. в 11:26
The mean of analysts' price targets for Ligand (LGND) points to a 38.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
New Strong Buy Stocks for May 5th
Zacks Investment Research
05 мая 2023 г. в 08:23
VREX, LGND, RNGR, SIGA and KMT have been added to the Zacks Rank #1 (Strong Buy) List on May 5, 2023.
Ligand Pharmaceuticals Incorporated (LGND) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 22:49
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2023 Results Conference Call May 4, 2023 4:30 PM ET Company Participants Simon Latimer - Head of Investor Relations Todd Davis - Chief Executive Officer Tavo Espinoza - Chief Financial Office Matthew Korenberg - President and Chief Operating Officer Conference Call Participants Scott Henry - ROTH Capital Matt Hewitt - Craig-Hallum Capital Joseph Pantginis - HC Wayne Wright Operator Thank you for standing by. My name is Kyla Baker and I will be your conference operator today.
Ligand Pharmaceuticals (LGND) Surpasses Q1 Earnings and Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:01
Ligand Pharmaceuticals (LGND) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.58 per share a year ago.